Centogene 因不符合市值要求而收到纳斯达克退市通知。 Centogene receives Nasdaq delisting notice for non-compliance with market value requirement.

Centogene 是一家专注于罕见和神经退行性疾病的生命科学公司，由于未遵守公开持有股票市值 1500 万美元的要求，收到了纳斯达克退市通知。 Centogene, a life sciences firm focusing on rare and neurodegenerative diseases, received a notice of delisting from Nasdaq due to non-compliance with the $15m Market Value of Publicly Held Shares requirement. 该公司计划要求举行听证会来解决该问题并防止停牌或退市。 The company plans to request a hearing to address the issue and prevent suspension or delisting. 尽管有通知，Centogene 将继续与战略合作伙伴合作，加速药物发现、开发和商业化。 Despite the notice, Centogene will continue working with strategic partners to accelerate drug discovery, development, and commercialization.